Chronic pain and peptides — a heterogeneous syndrome category where the peptide-pharmacology layer is mostly underused relative to its mechanistic potential

Why this dossier exists

Chronic pain is the syndrome category where the peptide-pharmacology layer is most clearly underused relative to its mechanistic potential, and where the gap between mechanism and validated therapeutic is widest in this corpus. The taxonomy itself is the first signal: the Treede RD, Rief W, Barke A et al., Pain 2019, 160:19–27 IASP/WHO classification adopted into ICD-11 split chronic pain into seven categories — chronic primary pain (nociplastic conditions such as fibromyalgia, chronic primary headache, complex regional pain syndrome, irritable bowel syndrome), chronic cancer-related pain, chronic postsurgical and posttraumatic pain, chronic neuropathic pain, chronic secondary headache and orofacial pain, chronic secondary visceral pain, and chronic secondary musculoskeletal pain. The framing is load-bearing because the mechanism layer differs across categories — what works for nociplastic primary pain differs from what works for chronic neuropathic or chronic cancer pain — and any "peptide approach to chronic pain" that does not name which pain it is addressing is operating below the resolution the modern taxonomy demands.

The US population scale is enormous and well-characterised. The Lucas JW, Sohi I, NCHS Data Brief 2025, no. 518 analysis of the 2023 National Health Interview Survey reported chronic pain prevalence of 24.3% of US adults and high-impact chronic pain (pain that limits life or work activities most days or every day in the past 3 months) of 8.5% — roughly 60 million and 21 million adults respectively on 2023 population denominators. Women carry higher prevalence (25.4% versus 23.2% in men for chronic pain; 9.6% versus 7.3% for high-impact chronic pain), American Indian and Alaska Native populations the highest stratum (30.7%), and prevalence rises monotonically with age across the working-life-to-elderly spectrum. The historical reference point — the Dahlhamer J, Lucas J, Zelaya C et al., MMWR Morb Mortal Wkly Rep 2018, 67:1001–1006 analysis of the 2016 NHIS that produced the canonical "50 million US adults with chronic pain, 20 million with high-impact" framing — has shifted upward in absolute count over the intervening seven years as the population aged.

This dossier walks the peptide-pathway therapeutic class across four threads: (1) intrathecal ziconotide as the FDA-approved peptide chronic-pain therapeutic — the only molecule in this corpus FDA-approved specifically for chronic-pain treatment; (2) oxytocin and the small but methodologically improving literature on its pain-modulating effects across fibromyalgia, low back pain, and visceral-pain populations; (3) BPC-157 musculoskeletal-pain practitioner use, with rodent and case-series evidence framed honestly against the absence of controlled human trials; (4) the GLP-1 receptor agonist class and the recent obesity-knee-osteoarthritis trial signal, with secondary-outcome pain data from the SELECT and STEP-HFpEF cardiometabolic programs. Three orthogonal contextual layers complete the frame: the substance P / NK1 antagonist story (a peptide-pathway target that failed clinically); the endogenous opioid peptide framework as biology rather than therapeutics; and the US Schedule II opioid landscape and the CDC clinical practice guideline for prescribing opioids that has motivated continuing interest in non-opioid pain pharmacology.